Welcome to our dedicated page for Protagonist Ther news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Ther stock.
News about Protagonist Therapeutics, Inc. (NASDAQ: PTGX) centers on its progress as a discovery-through-late-stage development biopharmaceutical company advancing peptide-based drug candidates. Company announcements frequently highlight clinical and regulatory milestones for its lead investigational therapies, icotrokinra and rusfertide, as well as updates from its broader pipeline and collaborations.
Investors following PTGX news will see regular coverage of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. Press releases describe data from Phase 3 ICONIC studies in moderate-to-severe plaque psoriasis, including ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2, as well as the Phase 2b ANTHEM-UC trial in ulcerative colitis. News items also report on regulatory submissions, such as the New Drug Application to the U.S. FDA and an application to the European Medicines Agency for plaque psoriasis.
Coverage of rusfertide focuses on its development for polycythemia vera in collaboration with Takeda. News releases describe Phase 3 VERIFY study results, long-term extension data from THRIVE, and the submission of a New Drug Application to the FDA for adults with polycythemia vera. These updates often include details on hematocrit control, phlebotomy requirements, patient-reported outcomes, and regulatory designations such as Breakthrough Therapy, Orphan Drug, and Fast Track status.
Additional PTGX news includes presentations at major medical and scientific conferences, such as the American Society of Hematology Annual Meeting, European Academy of Dermatology and Venereology Congress, American College of Gastroenterology meeting, and the J.P. Morgan Healthcare Conference. The company also issues periodic financial result and corporate update releases, which summarize recent clinical achievements, collaboration developments with Johnson & Johnson and Takeda, and progress in earlier-stage programs like PN-881, PN-477, and the oral hepcidin initiative.
For readers tracking PTGX, this news stream provides insight into Protagonist’s clinical data, regulatory interactions, partnership activities, and pipeline evolution as described in its own public communications.
Alpha Cognition Inc. (TSX-V: ACOG) announced the appointment of Don Kalkofen as Chief Financial Officer, replacing Jeremy Wright, who will remain as a consultant. Kalkofen has extensive experience in biotechnology finance, most recently as CFO at Protagonist Therapeutics (NASDAQ: PTGX), where he facilitated over $550 million in financing. He will lead Alpha Cognition's financial operations and support strategic growth. In conjunction with his appointment, Kalkofen received 450,000 stock options at $0.93 CAD. CEO Michael McFadden was also appointed to the board of directors.
Protagonist Therapeutics (Nasdaq: PTGX) announced the appointment of Asif Ali as Executive Vice President and CFO, effective mid-April 2022. Asif brings a strong background from Theravance Biopharma, focusing on financial planning and strategic partnerships. He has notable experience supporting product launches and acquisitions at Depomed. CEO Dinesh V. Patel expressed confidence in Asif's potential to enhance the company's financial operations and support its drug development pipeline, which includes therapies for polycythemia vera and ulcerative colitis.
Protagonist Therapeutics (PTGX) has initiated a Phase 2b clinical trial for PN-235, an oral IL-23 receptor antagonist targeting moderate-to-severe plaque psoriasis, with a planned enrollment of 240 patients. The trial commenced on February 3, 2022. The company also announced a $25 million milestone payment from Janssen Biotech for the dosing of the third patient in this trial. Protagonist is eligible for up to $850 million in development-related milestone payments from Janssen, which will oversee all future clinical studies.
Protagonist Therapeutics (PTGX) reported its fourth-quarter and full-year 2021 financial results, highlighting a net loss of $36.9 million in Q4 and $125.6 million for the year. The company emphasized significant progress in its pipeline, particularly with rusfertide entering a Phase 3 study for polycythemia vera and PN-943 completing enrollment for its Phase 2 study in ulcerative colitis. License and collaboration revenue rose to $8.6 million in Q4, up from $5.7 million in the previous year, driven by collaboration with Janssen. Cash reserves of $326.9 million are expected to support operations through 2024.
Protagonist Therapeutics (Nasdaq: PTGX) will be presenting at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 3:00 p.m. EST. The presentation by CEO Dinesh V. Patel will be available via live and archived webcast on their official website.
The company is advancing multiple clinical trials, including the REVIVE Phase 2 trial for rusfertide, aimed at treating polycythemia vera, and IDEAL Phase 2 study for PN-943 in ulcerative colitis.
Summary not available.
Protagonist Therapeutics (Nasdaq: PTGX) announced a virtual presentation by Dr. Dinesh V. Patel at the J.P. Morgan Healthcare Conference on January 11, 2022, at 2:15 a.m. EST. Dr. Patel will also participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. Both events will be accessible via the company's Investors website. Protagonist is advancing multiple peptide-based therapies, including rusfertide (PTG-300) for polycythemia vera and PN-943 for ulcerative colitis, along with collaboration on PN-235 with Janssen Biotech.
Protagonist Therapeutics (PTGX) presented promising data from two ongoing Phase 2 studies of rusfertide for polycythemia vera (PV) at the ASH 2021 Annual Meeting. Results show that 84% of patients eliminated the need for phlebotomy, with rapid hematocrit control observed. The Phase 3 trial is set to begin in early 2022.
Notably, the drug was well tolerated, with minimal severe adverse events reported. Rusfertide may also have implications in treating hereditary hemochromatosis.
Protagonist Therapeutics (Nasdaq: PTGX) has announced that Dinesh V. Patel, CEO, will present at the JMP Securities Hematology and Oncology Summit on December 6, 2021, at 1:40 p.m. EST. A webcast will be available for 90 days on the company’s Investors website. Protagonist focuses on peptide-based therapeutics, including rusfertide (PTG-300) for polycythemia vera and PN-943 for ulcerative colitis. They also collaborate with Janssen Biotech on oral IL-23 receptor antagonists. This upcoming presentation marks a key moment for stakeholders and potential investors.
Protagonist Therapeutics (Nasdaq: PTGX) announced PN-235 as its main candidate for clinical studies, focusing on the IL-23 pathway, following a collaboration with Janssen. The Phase 2 study for psoriasis is set to begin in early 2022, along with new studies for inflammatory bowel diseases expected later. Protagonist will earn $25 million for the psoriasis study and is eligible for $900 million in future milestones. The company will discontinue PN-232 in favor of PN-235 due to its superior profile.